Together, these data highlight the potential of DNMT3B as a robust prognostic marker for high risk disease independent from high risk cytogenetic abnormalities and imply a possible role for DNMT3B in MM disease progression and treatment resistance. The gene discussed is DNMT3B; the disease is Miyoshi myopathy.